TCR2 Therapeutics (TCRR) PT Raised to $57 at Wedbush, Following Earnings

March 11, 2021 2:01 PM EST
Get Alerts TCRR Hot Sheet
Price: $13.72 +7.44%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 45
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $57.00 (from $55.00) while maintaining a Outperform rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change

Related Entities